The Pay-Twice Critique, Government Funding, and Reasonable Pricing Clauses

• Published in: The Journal of legal medicine (Chicago. 1979) Vol. 39; no. 2; p. 177
• Main Author: Wolitz, Rebecca E
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis Ltd 01.04.2019
• Subjects: Clauses; Costs and Cost Analysis - economics; Costs and Cost Analysis - legislation & jurisprudence; Drug and Narcotic Control - economics; Drug and Narcotic Control - legislation & jurisprudence; Drug Costs - legislation & jurisprudence; Drugs; Federal Government; Financing, Government; Legislation, Drug - economics; National Institutes of Health (U.S.); Pharmaceutical Research - economics; Pharmaceutical Research - legislation & jurisprudence; Prescription drugs; Prescription Drugs - economics; Prescription Fees - legislation & jurisprudence; Prices; Pricing policies; Privatization - economics; Privatization - legislation & jurisprudence; United States; United States

The federal government subsidizes the research and development of prescription medications. Thus, a captivating critique of expensive medications is that prices are too high because of taxpayer co-financing. This critique is often framed in terms of "paying-twice"-first for the research an...